Chemotherapy News and Research

Latest Chemotherapy News and Research

FDA approves Zelboraf (vemurafenib) for advanced skin cancer

A new drug was approved for advanced skin cancer this Wednesday by U.S. regulators, offering the first new treatment for melanoma in 13 years.

18 Aug 2011

FDA approves Mayo Clinic's ovarian and breast cancer vaccines

Mayo Clinic has received investigational new drug approval from the Food and Drug Administration for two new cancer vaccines that mobilize the body's defense mechanisms to destroy malignant cells.

18 Aug 2011

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

Pfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer's regulatory submissions for review of two investigational compounds - crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, for the treatment of patients with previously treated ALK-positive advanced non-small cell lung cancer (NSCLC); and bosutinib for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) in the chronic phase.

18 Aug 2011

CEL-SCI receives Chinese patent for Multikine cancer drug

CEL-SCI Corporation today announced that the Chinese patent office has issued a key patent covering CEL-SCI's investigational cancer drug, Multikine.

18 Aug 2011

Syndax receives European patent allowance for entinostat to treat metastatic breast cancer

Syndax Pharmaceuticals, a clinical-stage epigenetics oncology company, today announced allowance by the European Patent Office for the patent application titled "N-(2-AMINOPHENYL)-4[N-(PYRIDINE-3-YL) - METHOXYCARBONYL - AMINOMETHYL]-BENZAMINE (MS-275) POLYMORPH B."

18 Aug 2011

Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma

Allos Therapeutics, Inc. today announced the enrollment of the first patient in a Phase 3 randomized clinical trial (PDX-017) evaluating FOLOTYN in patients with previously undiagnosed peripheral T-cell lymphoma.

18 Aug 2011

Roche receives FDA approval for Zelboraf to treat BRAF mutation-positive metastatic melanoma

Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved Zelboraf (vemurafenib) for the treatment of BRAF V600E mutation-positive, inoperable or metastatic melanoma, as determined by an FDA-approved test.

18 Aug 2011

Emergent commences TRU-016 Phase 1b/2 combination trial in relapsed indolent NHL

Emergent BioSolutions Inc. today announced the initiation of a Phase 1b/2 study (16011) of TRU-016 in combination with rituximab and bendamustine for patients with relapsed indolent non-Hodgkin's B-cell lymphomas, including follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma.

17 Aug 2011

Clinical trial to assess 6MP drug in women with advanced breast or ovarian cancer

A CANCER RESEARCH UK-funded trial of a new drug for patients with advanced breast or ovarian cancer due to inherited gene faults has been launched at the Oxford Experimental Cancer Medicine Centre (ECMC) at the University of Oxford.

17 Aug 2011

Drug SLM3 prevents multiplication of tumor cells

Tumors that do not respond to chemotherapy are the target of a cancer therapy that prevents the function of two enzymes in mouse tumor cells, according to Pennsylvania medical researchers.

17 Aug 2011

Patrys product shows activity in multiple myeloma cancer cells

Patrys Limited today announced the results of preclinical work conducted at The University Hospital of Würzburg showing the activity of one of Patrys’ products in multiple myeloma.

16 Aug 2011

IMRT produces high response rate in patients with extranodal lymphoma of head and neck: Research

Lymphoma is a cancer that affects organs of the immune system, including the lymph nodes. In a subtype of the disease called extranodal lymphoma, tumors arise in non-lymphoid organs, such as the tongue and tonsils.

16 Aug 2011

Customized computer models may identify patients at risk of Lynch syndrome

People who are at risk for a certain form of colon and other types of cancer may soon have a better chance at surviving or even avoiding the diseases, thanks to a new study done by the Intermountain Clinical Genetics Institute at LDS Hospital.

16 Aug 2011

Scientists identify potential new target for childhood eye tumor

A research team led by St. Jude Children's Research Hospital scientists has identified a potential new target for treatment of the childhood eye tumor retinoblastoma.

16 Aug 2011

Targeted therapies that attack stem cell-like cancer cells can prevent spread of prostate cancer

A successful interdisciplinary project is underway between two research groups, in which senior researcher Rebecka Hellsten and Professor Anders Bjartell at the Faculty of Medicine's division for Urological Cancer Research, Sk-ne University Hospital in Malm-, and Professor Olov Sterner and Assistant Professor Martin Johansson at the Lund University division of Organic Chemistry recently published their latest research findings in the scientific online journal PLoS ONE.

12 Aug 2011

Galectin second quarter net loss increases to $3.9 million

Galectin Therapeutics Inc., the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the second quarter and first six months, ended June 30, 2011.

12 Aug 2011

Researchers to develop new prostate cancer therapy

Prostate cancer that has become resistant to hormone treatment and that does not respond to radiation or chemotherapy requires new methods of treatment. By attacking stem cell-like cells in prostate cancer, researchers at Lund University are working on a project to develop a new treatment option.

12 Aug 2011

Trastuzumab drug increases risk of heart problems in elderly breast cancer patients

The first study to investigate the effect of the breast cancer drug trastuzumab (Herceptin) on heart and vascular function in elderly patients has found that it increases the risk of heart problems, particularly in women with a history of heart disease, diabetes or both.

10 Aug 2011

BIDMC researchers receive PCF Challenge Awards for novel prostate cancer study

Beth Israel Deaconess Medical Center (BIDMC) researchers Martin Sanda, MD, and Steven Balk MD, PhD, have been awarded Challenge Awards of $1 million each from the Prostate Cancer Foundation (PCF) to lead two cross-disciplinary teams of investigators in their pursuit of new treatments for patients with advanced prostate cancer.

10 Aug 2011

Novel therapy shrinks tumors without collateral damage

A potential new option is beginning to emerge for patients with the fastest growing form of cancer in the United States, according to researchers at the University of Alabama at Birmingham.

10 Aug 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

FDA approves Zelboraf (vemurafenib) for advanced skin cancer

FDA approves Mayo Clinic's ovarian and breast cancer vaccines

EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for review

CEL-SCI receives Chinese patent for Multikine cancer drug

Syndax receives European patent allowance for entinostat to treat metastatic breast cancer

Enrollment commences in Allos' FOLOTYN Phase 3 trial for peripheral T-cell lymphoma

Roche receives FDA approval for Zelboraf to treat BRAF mutation-positive metastatic melanoma

Emergent commences TRU-016 Phase 1b/2 combination trial in relapsed indolent NHL

Clinical trial to assess 6MP drug in women with advanced breast or ovarian cancer

Drug SLM3 prevents multiplication of tumor cells

Patrys product shows activity in multiple myeloma cancer cells

IMRT produces high response rate in patients with extranodal lymphoma of head and neck: Research

Customized computer models may identify patients at risk of Lynch syndrome

Scientists identify potential new target for childhood eye tumor

Targeted therapies that attack stem cell-like cancer cells can prevent spread of prostate cancer

Galectin second quarter net loss increases to $3.9 million

Researchers to develop new prostate cancer therapy

Trastuzumab drug increases risk of heart problems in elderly breast cancer patients

BIDMC researchers receive PCF Challenge Awards for novel prostate cancer study

Novel therapy shrinks tumors without collateral damage

Cancer Research - Second Edition eBook

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

How does norepinephrine influence anxiety-related behaviours?

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Newsletters you may be interested in